ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøվʼÖÕÖÂÁ¦ÓÚÒԵײãÊÖÒÕÍ»ÆÆÍƶ¯Á¢ÒìÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾²úÆ·¹ÜÏßÉú³¤£¬£¬£¬£¬£¬£¬»ùÓÚÐÂÒ»´ú»ùÒòдÈëϵͳ¡¢ÄÉÃ׿¹ÌåÊÖÒÕ¼°¸ßÆ·ÖÊmRNAºÏ³ÉÊÖÒյȵײãÊÖÒÕµÄÍ»ÆÆ£¬£¬£¬£¬£¬£¬¿ª·¢³öÄÉÃ׿¹Ìå×°¼×»¯CAR-T¡¢¶à°ÐµãCAR-T¼°ÄÉÃ׿¹Ìå×°¼×»¯DCÒßÃçµÈÁ¢Òì²úƷƽ̨¡£¡£¡£¡£¡£¡£¡£¡£

BaizeDCÒßÃçÊǼ¯ÍÅ»ùÓÚºËËáµ×²ãÌ«ÖÊÁ£ÊÖÒÕ¡¢mRNAÊÖÒÕ¼°ÄÉÃ׿¹ÌåÊÖÒÕÑз¢µÄÒ»¿îÐÂÐÍÄÉÃ׿¹Ìå×°¼×»¯Ê÷Í»×´ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¨DC£©ÒßÃç¡£¡£¡£¡£¡£¡£¡£¡£ÆäÆæÒìÖ®´¦ÔÚÓÚͨ¹ýFast DCÊÖÒÕƽ̨¾ÙÐÐÁ˹¤ÒÕˢУ¬£¬£¬£¬£¬£¬ÊµÏÖ¿ìËÙDCÒßÃçÖƱ¸£¨3ÌìÄÚ£©£¬£¬£¬£¬£¬£¬¸ßЧ¸ºÔØÖ×Áö¿¹Ô­²¢¸ßˮƽ±í´ïPD-1&CTLA4Ë«ÌØÒìÄÉÃ׿¹Ì壬£¬£¬£¬£¬£¬²¢¿ìËÙÍƽøÖÁÁÙ´²¿ª·¢½×¶Î¡£¡£¡£¡£¡£¡£¡£¡£BaizeDCÒßÃçÖ¼ÔÚ¸üÓÐÓõؼ¤»î»¼Õß×ÔÉíµÄÃâÒßϵͳ£¬£¬£¬£¬£¬£¬ÓÐÍûÏÔÖø¸ÄÉÆÖ×ÁöÃâÒß¼àÊÓˮƽ£¬£¬£¬£¬£¬£¬´Ó¶ø½µµÍÖ×Áö¸´·¢ÂÊ£¬£¬£¬£¬£¬£¬Îª°©Ö¢»¼ÕßÌṩеÄÖÎÁÆÏ£Íû¡£¡£¡£¡£¡£¡£¡£¡£

ÕâһǰÑØÐÔÑо¿Ð§¹ûÓÚ¿ËÈÕÏȺ󱻹ú¼ÊȨÍþѧÊõ¾Û»áµÚ4½ì¹ú¼ÊÒßÃç´ó»á£¨4th International Vaccines Congress (IVC) 2024£©ºÍ°©Ö¢ÃâÒßÁÆ·¨Ð­»áµÚ39½ìÄê»á£¨the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting£©ÊÕ¼²¢Ô¼Çë¾ÙÐоۻᱨ¸æ¡£¡£¡£¡£¡£¡£¡£¡£

IVCºÍSITC¶¼ÊÇÃâÒßѧÁìÓòµÄ¹ú¼ÊÊ¢»á¡£¡£¡£¡£¡£¡£¡£¡£±¾½ìIVC´ó»áÒÔ“ÔöÇ¿ÃâÒßÁ¦£ºÕ¹ÏÖÒßÃç¿ÆѧÁ¢Òì”ΪÖ÷Ì⣬£¬£¬£¬£¬£¬ËѼ¯ÁËÀ´×ÔÌìϸ÷µØ×ÅÃû»ú¹¹µÄÓÅÒìÖ÷Ö¼Ñݽ²Õß¡¢×¨¼ÒºÍ´ú±í¡£¡£¡£¡£¡£¡£¡£¡£SITCÄê»áÔòÊÇרעÓÚÖ×ÁöÃâÒßÖÎÁÆ£¬£¬£¬£¬£¬£¬ÎªÈ«ÇòÊýǧÃûѧÊõ½ç¡¢î¿Ïµ»ú¹¹µÄÐÐÒµÊ×ÄÔÌṩÁËÒ»¸ö¶àѧ¿Æ½»Á÷µÄƽ̨£¬£¬£¬£¬£¬£¬ÖÂÁ¦ÅäºÏÍƶ¯¿Æѧǰ½ø£¬£¬£¬£¬£¬£¬·¢Ã÷Í»ÆÆÐÔµÄÏ£Íû£¬£¬£¬£¬£¬£¬¸ÄÉÆ°©Ö¢»¼ÕßµÄÔ¤ºó¡£¡£¡£¡£¡£¡£¡£¡£

ͼ IVC2024¾Û»áÔ¼ÇëÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÐÂÒ©´´ÔìBG×ܲÃÁõÒò©Ê¿¾ÙÐпÚÍ·±¨¸æ

ͼ SITC¾Û»áÊÕ¼ÄÉÃ׿¹Ìå×°¼×»¯DCÖ×ÁöÒßÃçµÄ×îÐÂÑо¿Ï£Íû£¨posterչʾ£¬£¬£¬£¬£¬£¬ÕªÒªºÅ£º1041£©

ÒÔÏÂΪÁõÒò©Ê¿¶ÔÄÉÃ׿¹Ìå×°¼×»¯DCÖ×ÁöÒßÃçµÄ×îÐÂÑо¿Ï£Íû±¨¸æµÄ²¿·ÖÄÚÈÝ£º

»ã±¨ÎÊÌ⣺

Development of nanobody-armored DC vaccine(BaizeDC) and its preliminary exploration in preventing solid tumor recurrence

ÕªÒªÖ÷ÒªÄÚÈÝ£º

ͼ BaizeDC²úÆ·Éè¼ÆºÍ×÷ÓûúÖÆ

BaizeDCÊÇÒ»ÖÖÄÉÃ׿¹Ìå×°¼×»¯DCÒßÃç²úÆ·£¬£¬£¬£¬£¬£¬±í´ïp53ºÍSurvivinÖ×ÁöÏà¹Ø¿¹Ô­£¨TAA£©£¬£¬£¬£¬£¬£¬Í¬Ê±Éø͸αPD-1/CTLA-4Ë«ÌØÒìÐÔÄÉÃ׿¹Ìå¡£¡£¡£¡£¡£¡£¡£¡£Í¨¹ýµç´©¿×½«±àÂëTAAsµÄmRNAºÍ±àÂëÄÉÃ׿¹ÌåµÄСÖÊÁ£Tiniplasmidתµ¼ÖÁDC¡£¡£¡£¡£¡£¡£¡£¡£±í´ïµÄTAA±»DCÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¼Ó¹¤³ÊµÝ£¬£¬£¬£¬£¬£¬×÷Ϊ»î»¯TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄµÚÒ»Ðźţ¬£¬£¬£¬£¬£¬ÓÕµ¼TAAÌØÒìÐÔTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¼¤»î¡£¡£¡£¡£¡£¡£¡£¡£¸üΪÖ÷ÒªµÄÊÇBaizeDCÉø͸α-PD-1/CTLA4ÄÉÃ׿¹Ì壬£¬£¬£¬£¬£¬¿Éͨ¹ý×è¶ÏB7-CTLA-4ºÍPD-1-PD-L1Ï໥×÷ÓöøÏ÷ÈõÃâÒßÒÖÖÆ¡£¡£¡£¡£¡£¡£¡£¡£ÕâÖÖ»úÖÆ¿ÉÒÔÔö½øµÍÃâÒßÔ­ÐÔµÄTAAÌØÒìÐÔTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄÓÕµ¼ºÍ¼¤»î¡£¡£¡£¡£¡£¡£¡£¡£

ͼ BaizeDCÖƱ¸Á÷³Ì

ΪÁË»ñµÃ¹¦Ð§¸üÖÜÈ«µÄDC£¬£¬£¬£¬£¬£¬ »ùÓÚFastDC¼Æ»®¶Ô¹¤ÒÕ¾ÙÐÐÁËˢУ¬£¬£¬£¬£¬£¬ÔÚÈýÌìÄÚÌìÉúBaizeDCÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¡£¡£¡£¡£¡£¡£¡£¡£¼òÒªµØ£¬£¬£¬£¬£¬£¬´ÓPBMCÖÐÊèÉ¢µ¥ºËÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬£¬£¬ÓÃGM-CSFºÍIL-4ÔÚ48СʱÄÚÓÕµ¼Î´³ÉÊìµÄDC¡£¡£¡£¡£¡£¡£¡£¡£È»ºó£¬£¬£¬£¬£¬£¬ÓÃרÃŵijÉÊìÓÕµ¼ÊÔ¼Á×éºÏ×÷ÓýÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾,  24Сʱºó»ñµÃ³ÉÊìDC£¬£¬£¬£¬£¬£¬È»ºóµç´©¿×TAA mRNAºÍ±í´ïÄÉÃ׿¹ÌåµÄTiniplasmid£¬£¬£¬£¬£¬£¬ÊÕ»ñ»ñµÃ¸ß´¿¶È£¨>90%£©ºÍ¸ß»îÂÊ£¨>80%£©µÄBaizeDC¡£¡£¡£¡£¡£¡£¡£¡£

ͼ BaizeDCµÄÌåÍ⹦ЧÆÊÎö

ͨ¹ýTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¹²×÷Óý£¬£¬£¬£¬£¬£¬Óë·Ç×°¼×»¯DCÏà±È£¬£¬£¬£¬£¬£¬BaizeDC¿ÉÒÔ¼¤»î¸ü¶àµÄTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¨TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¼¤»î±ê¼ÇÎïCD69+ºÍCD25+TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾±ÈÀý£©£¬£¬£¬£¬£¬£¬±¬·¢¸ü¶àµÄÖ×Áö¿¹Ô­ÌØÒìÐÔTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¨Éø͸IFN-γµÄTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬£¬£¬200 spot/105 cells vs 100 spot/105 cells£©¡£¡£¡£¡£¡£¡£¡£¡£BaizeDC»î»¯µÄTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¶ÔHepG2Ö×ÁöÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÌåÏÖ³ö¸üÇ¿µÄÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøվɱÉË¡£¡£¡£¡£¡£¡£¡£¡£

ͼ BaizeDCÌåÏÖ³ö¸ßˮƽÑ×ÐÔÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Òò×ÓÉø͸¡¢³ÉÊì±ê¼ÇÎïºÍÁÜͶºÏǨáãÄÜÁ¦Ïà¹Ø±ê¼ÇÎï

Óë·Ç×°¼×DCÏà±È£¬£¬£¬£¬£¬£¬BaizeDCÏÔʾ³ö¸ü¸ßµÄIL-12ºÍTNF-αÉø͸ˮƽ¡£¡£¡£¡£¡£¡£¡£¡£¿£¿£¿£¿£¿£¿£¿£¿¹Ô­µÝ³Ê·Ö×ÓHLA-ABC / HLA-DRºÍ¹²´Ì¼¤·Ö×ÓCD83 / CD80 / CD86 / CD40µÄËùÓÐÉúÎï±ê¼ÇÎï¾ù¼á³ÖÔÚ90%ÒÔÉϵĸßˮƽ£¬£¬£¬£¬£¬£¬Åú×¢DCÒѾ­³ä·Ö³ÉÊì²¢±»¼¤»î¡£¡£¡£¡£¡£¡£¡£¡£ÖµµÃ×¢ÖصÄÊÇ£¬£¬£¬£¬£¬£¬BaizeDC±í´ïÁ˸ßˮƽµÄCCR7£¬£¬£¬£¬£¬£¬ CCR7ÊÇDCǨáãµÄÒªº¦±ê¼ÇÎ£¬£¬£¬£¬£¬ÕâÓÐÀûÓÚBaizeDCÔÚÌåÄÚµÄǨáã¡£¡£¡£¡£¡£¡£¡£¡£

ͼ ÁÙ´²Ñо¿Éè¼ÆºÍÖ÷ÒªÈëÅűê×¼

»ùÓÚÆð¾¢µÄÁÙ´²Ç°Ñо¿Ð§¹û£¬£¬£¬£¬£¬£¬ÎÒÃÇ¿ªÕ¹ÁËÒ»Ïîµ¥±Û¡¢¿ª·Å±êÇ©µÄÊ×´ÎÈËÌåÑо¿£¬£¬£¬£¬£¬£¬ÒÔÆÀ¹ÀBaizeDCµÄÇå¾²ÐÔºÍÓÐÓÃÐÔ¡£¡£¡£¡£¡£¡£¡£¡£Ö÷ÒªÖÕµãÊDz»Á¼ÊÂÎñ£¨AE£©µÄƵÂʺÍÑÏÖØˮƽ¡£¡£¡£¡£¡£¡£¡£¡£´ÎÒªÖÕµã°üÀ¨ÎÞ²¡ÉúÑÄÆÚ£¨DFS£©¡¢×ÜÉúÑÄÆÚ£¨OS£©¡¢Ò©´ú¶¯Á¦Ñ§£¨PK£©ºÍÖ×ÁöÌØÒìÐÔÃâÒß·´Ó¦¡£¡£¡£¡£¡£¡£¡£¡£

ͼ ÎÞ²¡ÉúÑÄ£¨DFS£©Ð§¹û

ËùÓÐ4Ãû»¼Õß¾ùÍê³ÉÁË8¼ÁBaizeDC×¢É䣬£¬£¬£¬£¬£¬Ã¿¼ÁÓÉ1×10?ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾×é³É¡£¡£¡£¡£¡£¡£¡£¡£»£»£»£»£»£»¼Õßÿ3¸öÔÂËæ·ÃÒ»´ÎCT»òPET-CTÓ°Ïñѧ¼ì²é¡£¡£¡£¡£¡£¡£¡£¡£×èÖ¹µ½2024Äê9ÔÂ20ÈÕ£¬£¬£¬£¬£¬£¬ËùÓÐ4Àý»¼Õß¾ùÎÞ¸´·¢£¬£¬£¬£¬£¬£¬ÖÐλËæ·Ãʱ¼äΪ11.6¸öÔ¡£¡£¡£¡£¡£¡£¡£¡£

½áÂÛ

·BaizeDCÊÇÒ»ÖÖ»ùÓÚDCµÄ×ÔÌåÖ×ÁöÒßÃ磬£¬£¬£¬£¬£¬Í¨¹ýÉø͸˫ÌØÒìÐÔαPD-1/CTLA-4ÄÉÃ׿¹Ìå×°¼×»¯²¢±í´ïp53ºÍSurvivinÖ×ÁöÏà¹Ø¿¹Ô­¡£¡£¡£¡£¡£¡£¡£¡£BaizeDCÖÎÁÆÊÇÔ¤·ÀʵÌåÁöÊÖÊõÇгýºó¸´·¢µÄÒ»ÖÖÁ¢ÒìÑ¡Ôñ¡£¡£¡£¡£¡£¡£¡£¡£

·BaizeDC¶à´Î×¢ÉäÄÍÊÜÐÔÓÅÒ죬£¬£¬£¬£¬£¬Ñо¿ÖÐλËæ·Ãʱ¼äΪ11.6¸öÔ£¬£¬£¬£¬£¬£¬ÏÔʾ³öDZÔÚµÄÁÙ´²»ñÒæ¡£¡£¡£¡£¡£¡£¡£¡£

·ÎªÁËÌá¸ßÁÙ´²ÁÆЧ£¬£¬£¬£¬£¬£¬ÕýÔÚ¶Ô¿¹Ô­ÃâÒßÔ­ÐÔºÍÄÉÃ׿¹Ìå¾ÙÐнøÒ»²½ÓÅ»¯£¬£¬£¬£¬£¬£¬¿ª·¢ÏÂÒ»´úBaizeDCÒßÃç¡£¡£¡£¡£¡£¡£¡£¡£